Elutia (ELUT) vs Kalaris Therapeutics (KLRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Elutia (ELUT) has outperformed Kalaris Therapeutics (KLRS) over the past year, gaining 52.6% versus a loss of 81.7%. Over five years, ELUT leads with a -82.8% price change compared with -99.7% for KLRS. Elutia is the larger company by market cap ($40.0 million vs $30.5 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELUT | KLRS |
|---|---|---|
| Share price | $0.9001 | $1.28 |
| Market cap | $39.96M | $30.47M |
| 1-day change | +11.12% | -5.19% |
| YTD return | +29.88% | -84.83% |
| 1-year return | +52.56% | -81.74% |
| 5-year return | -82.76% | -99.70% |
| EPS (TTM) | $-0.68 | $-1.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $12.29M | — |
| Revenue growth (YoY) | -15.03% | — |
| Net income (latest FY) | $53.38M | $-43.44M |
| Gross margin | 53.66% | — |
| Operating margin | -218.91% | — |
| Net margin | 434.23% | — |
| 52-week high | $1.39 | $11.88 |
| 52-week low | $0.50 | $1.25 |
| Distance from 52-week high | -35.01% | -89.23% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +455.49% | +1361.72% |
| Average volume | 185.17K | 77.37K |
| Shares outstanding | 44.40M | 23.80M |
| Employees | 25 | 20 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ELUT has outperformed KLRS by 134.3 percentage points over the past year.
About Elutia
ELUT stock →Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 25 employees
About Kalaris Therapeutics
KLRS stock →Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
ELUT vs KLRS FAQ
Which is bigger, Elutia or Kalaris Therapeutics?
Elutia (ELUT) is larger, with a market capitalization of $39.96M compared with $30.47M for Kalaris Therapeutics (KLRS).
Which stock has performed better over the past year, ELUT or KLRS?
ELUT returned +52.56% over the past 12 months, compared with -81.74% for KLRS (price return, excluding dividends). Past performance does not predict future results.
Are Elutia and Kalaris Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.